Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV 2 Formulation 4 (Sanofi)
- Development stage
- Discontinued
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**HSV 2 Formulation 4** was an investigational intramuscular therapeutic vaccine formulation evaluated by Sanofi in the terminated HSV15 Phase 1/2a study for recurrent genital herpes caused by herpes simplex virus type 2. Trial-regimen information and Sanofi's study summary indicate that this formulation corresponds to **adjuvanted HSV529**, a replication-defective HSV-2 vaccine administered with the GLA-SE adjuvant, used as the priming vaccination before G103 in a sequential prime-boost regimen. HSV529 is designed to expose the immune system to HSV-2 antigens without productive viral replication in normal cells, promoting HSV-specific humoral and cellular immune responses. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT04222985/))
- Other names
- adjuvanted HSV529HSV529 + GLA-SE
02
Targets
ICP4 (Infected cell protein 4)gD (HSV-2 glycoprotein D)TLR4 (Toll-like receptor 4)HSV-2 gC/gD/gE (Herpes simplex virus type 2 glycoproteins C/D/E)
Beyond the preview
Go deeper on HSV 2 Formulation 4 (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV 2 Formulation 4 (Sanofi).